Fotivda Capsule
Product Images NDC 45629-089

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Fotivda (NDC 45629-089). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aveo Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Fotivda 01)

Chemical Structure (Fotivda 01)
Chemical structure diagram of Tivozanib, the active ingredient in FOTIVDA. The diagram includes labeled atoms and structural groups, along with hydrochloride (HCl) and water (H2O) components.*
FDA Label Image

Figure 1 (Fotivda 02)

Figure 1 (Fotivda 02)
This is a Kaplan-Meier survival curve graph showing progression-free survival probability over time (months) comparing two treatment groups: FOTIVDA and Sorafenib. The graph includes a plotted survival curve for each treatment, with FOTIVDA represented by a blue dotted line and Sorafenib by a green dashed line. Censored data points are marked with plus signs. Below the graph is a table listing the number of subjects at risk in each group at various time points up to 26 months.*
FDA Label Image

Principal Display Panel (0.89 mg Capsule Bottle Label)

Principal Display Panel (0.89 mg Capsule Bottle Label)
FOTIVDA (tivozanib) capsules 0.89 mg oral capsules label by AVEO Pharmaceuticals, Inc. The label states the active ingredient strength, specifies it is manufactured in Japan by Catalent CTS, Inc., and provides storage and dosage information. It includes regulatory and barcode details, along with the AVEO Oncology logo.*
FDA Label Image

Principal Display Panel (1.34 mg Capsule Bottle Label)

Principal Display Panel (1.34 mg Capsule Bottle Label)
FOTIVDA (tivozanib) capsules label showing 1.34 mg strength. The oral capsule packaging includes the AVEO Pharmaceuticals, Inc. and AVEO Oncology logos. The label indicates 21 capsules per container and notes prescription-only status and recommended storage conditions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.